Registry Study for Optimal Management of Liver Failure in the Chinese Population (RESOLVE-C)
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Enrollment
- 500
- Locations
- 14
- Primary Endpoint
- Overall survival
Study Overview
Brief Summary
Liver failure is the most severe form of liver damage caused by viral, alcoholic, drug-related and ischemia-reperfusion factors, often combined with extrahepatic organ damage, resulting in a high mortality rate. This study intends to construct a real-world case registry database of inpatients with liver failure based on an electronic clinical data collection system through a multicenter collaborative network to study the clinical characteristics, epidemiology of bacterial and fungal infections, the impact of sarcopenia on clinical prognosis, and optimization of treatment strategies such as antiviral and artificial liver in Chinese inpatients with liver failure. The cohort and experience generated from this study will be used as a support for a series of future studies to focus on clinical issues such as infection, end-stage liver disease combined with organ failure, and early warning of critically ill patients.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Other
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients with a diagnosis consistent with liver failure and pre-liver failure:
- •Extreme weakness with significant gastrointestinal symptoms such as anorexia, vomiting and abdominal distention;
- •Elevated alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) with progressive jaundice (TBil≥85.5 μmol/L);
- •Bleeding tendency with PTA ≤ 60% or INR ≥ 1.5.
Exclusion Criteria
- •An event or complication that, in the judgment of the investigator, significantly affects the assessment of clinical status.
Outcomes
Primary Outcomes
Overall survival
Time Frame: 90-day
90-day survival rates without liver transplantation
Secondary Outcomes
- Disease progression(48 weeks after discharge)